0001209191-17-052872.txt : 20170914 0001209191-17-052872.hdr.sgml : 20170914 20170914193105 ACCESSION NUMBER: 0001209191-17-052872 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170913 FILED AS OF DATE: 20170914 DATE AS OF CHANGE: 20170914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azelby Robert CENTRAL INDEX KEY: 0001656998 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 171086616 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE 300 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-13 0 0001594864 Juno Therapeutics, Inc. JUNO 0001656998 Azelby Robert C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP & Chief Commercial Officer Common Stock 2017-09-13 4 S 0 12850 44.95 D 37439 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017. /s/ Zachary D. Hale, attorney-in-fact 2017-09-14